NY-ESO-1 antibody as a novel tumour marker of gastric cancer.
NY-ESO-1 antibody as a novel tumour marker of gastric cancer.
复制标题
DOI：
10.1038/bjc.2013.51
复制
发表时间：
2013-03-19
影响因子：
8.8
通讯作者：
Doki, Y.
中科院分区：
文献类型：
--
作者：
Fujiwara, S.;Wada, H.;Kawada, J.;Kawabata, R.;Takahashi, T.;Fujita, J.;Hirao, T.;Shibata, K.;Makari, Y.;Iijima, S.;Nishikawa, H.;Jungbluth, A. A.;Nakamura, Y.;Kurokawa, Y.;Yamasaki, M.;Miyata, H.;Nakajima, K.;Takiguchi, S.;Nakayama, E.;Mori, M.;Doki, Y.
NY-ESO-1抗体在NY-ESO-1表达肿瘤患者中特异性观察到。我们分析了NY-ESO-1体液免疫应答是否是胃癌的有用肿瘤标志物。采用酶联免疫吸附试验（ELISA）检测363例胃癌患者血清中NY-ESO-1抗体。从25例NY-ESO-1抗体阳性患者中获得系列血清样本，其中包括16例根治性切除患者和9例仅接受化疗的患者。NY-ESO-1抗体在3.4%的I期、4.4%的II期、25.3%的III期和20.0%的IV期患者中检测到。抗体阳性的频率随着疾病的进展而增加。当NY-ESO-1抗体与癌胚抗原和CA 19 -9联合用于检测胃癌时，观察到III期和IV期患者的信息增益为11.2%，所有患者的信息增益为5.8%。术后未复发患者的NY-ESO-1免疫应答水平低于临界水平。2例复发患者显示不完全降低。接受单独化疗的9名患者继续显示NY-ESO-1免疫应答。当与常规肿瘤标志物结合时，NY-ESO-1体液免疫应答可能是检测进展期胃癌和推断血清阳性患者治疗后肿瘤负荷的有用肿瘤标志物。
NY-ESO-1 antibodies are specifically observed in patients with NY-ESO-1-expressing tumours. We analysed whether the NY-ESO-1 humoral immune response is a useful tumour marker of gastric cancer. Sera from 363 gastric cancer patients were screened by enzyme-linked immunosorbent assay (ELISA) to detect NY-ESO-1 antibodies. Serial serum samples were obtained from 25 NY-ESO-1 antibody-positive patients, including 16 patients with curative resection and 9 patients who received chemotherapy alone. NY-ESO-1 antibodies were detected in 3.4% of stage I, 4.4% of stage II, 25.3% of stage III, and 20.0% of stage IV patients. The frequency of antibody positivity increased with disease progression. When the NY-ESO-1 antibody was used in combination with carcinoembryonic antigen and CA19-9 to detect gastric cancer, information gains of 11.2% in stages III and IV, and 5.8% in all patients were observed. The NY-ESO-1 immune response levels of the patients without recurrence fell below the cutoff level after surgery. Two of the patients with recurrence displayed incomplete decreases. The nine patients who received chemotherapy alone continued to display NY-ESO-1 immune responses. When combined with conventional tumour markers, the NY-ESO-1 humoral immune response could be a useful tumour marker for detecting advanced gastric cancer and inferring the post-treatment tumour load in seropositive patients.
登录
查看更多内容
影响因子：
168.9
作者：
Klein, CA;Blankenstein, TJF;Riethmüller, G
通讯作者：
Riethmüller, G
DOI：
10.1038/nrc3239
发表时间：
2012-03-22
期刊：
Nature reviews. Cancer
影响因子：
--
作者：
Pardoll DM
通讯作者：
Pardoll DM
影响因子：
6.2
作者：
NAKASHIMA, H;INOUE, H;AKIYOSHI, T
通讯作者：
AKIYOSHI, T
影响因子：
8.4
作者：
Motoori, Masaaki;Takemasa, Ichiro;Kato, Kikuya
通讯作者：
Kato, Kikuya
影响因子：
45.3
作者：
Sasako, Mitsuru;Sakuramoto, Shinichi;Ohashi, Yasuo
通讯作者：
Ohashi, Yasuo